Skip to main content

Market Overview

Merck' Keytruda Plus Eisai's Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To Chemo

Share:

Merck & Co (NYSE: MRK) has announced data from Phase 3 KEYNOTE-775/Study 309 trial evaluating Keytruda combined with Eisai Co Ltd's (OCTMKTS: ESALY) Lenvima for advanced, metastatic, or recurrent endometrial cancer following one prior platinum-based regimen in any setting.

  • The data were presented at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer. 
  • A statistically significant and clinically meaningful improvement in PFS was seen in the all-comer population. Keytruda plus Lenvima reduced the risk of disease progression or death by 44%, with a median PFS of 7.2 months versus 3.8 months for patients who received chemotherapy.
  • Keytruda plus Lenvima reduced the risk of death by 38%, with a median OS of 18.3 months versus 11.4 months in patients who received physician's choice chemotherapy.
  • In the all-comer population, the objective response rate was 31.9%, with a complete response (CR) rate of 6.6% and a partial response (PR) rate of 25.3%, in Keytruda plus Lenvima group, versus 14.7%, with a CR rate of 2.6% and a PR rate of 12.0% in the chemo group.
  • For patients who responded, the median duration of response (DOR) was 14.4 months for patients in the Keytruda plus Lenvima arm versus 5.7 months in the chemotherapy arm.
  • KEYNOTE-775/Study 309 is the confirmatory trial for KEYNOTE-146/Study 111, which supported the FDA 2019 accelerated approval of Keytruda plus Lenvima combination for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
  • Price Action: MRK shares are trading 0.43% higher at $77.6 in the premarket on the last check Friday.
 

Related Articles (MRK + ESALF)

View Comments and Join the Discussion!

Posted-In: Endometrial CancerBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com